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The orchestration of transcriptional programs depends on proper gene-enhancer pairing. While much
remains to be learned about this process in normal development, two recent studies in Cell (Gro¨schel and
colleagues) and this issue of Cancer Cell (Yamazaki and colleagues) highlight how the genomic rearrange-
ment of an enhancer plays a causal role in the onset of a leukemogenic program.Genetic lesions are well-chronicled
drivers of various malignancies, with evi-
dence accumulating from early cytoge-
netic studies as well as modern molecular
techniques. The majority of such tech-
niques have placed an emphasis on the
amplification, deletion, or rearrangement
of coding sequences and have success-
fully identified hundreds of important
drivers in cancer (Garraway and Lander,
2013). However, the vast expanse of non-
coding sequence in mammalian genomes
is known to contain regulatory elements
that contribute to the control of gene
expression and could therefore influence
gene expression via mutation, rearrange-
ment, deletion, or amplification. Prece-
dence for the involvement of such ele-
ments in oncogenesis has been set
by the demonstration that expression of
MYC and other oncogenes can be de-
regulated in lymphoid cells via juxtaposi-
tion of the immunoglobulin heavy chain
regulatory regions, which drive aberrant
expression (ar-Rushdi et al., 1983). A
more recent demonstration of the impor-
tance of mutations in regulatory regions
was the identification of mutations in telo-
merase promoter regions in melanoma
(Huang et al., 2013). However, it remains
unclear how and to what extent deregula-
tion of oncogene expression as a result
of mutations in gene regulatory regions
drives cancer pathogenesis.
Enhancer elements are regions of DNA
that function as distal, nonpromoter, cis-
acting regulators of gene expression that
often operate in a tissue-specific manner.
As an area that has not been queried by
traditional technologies, such regulatory
elements remain at the frontier in the
study of both normal and aberrant geneexpression, with the latter containing im-
plications for the regulation of putative
oncogenic drivers. Key challenges in the
study of enhancers involve difficulties in
their initial identification and the identifi-
cation of the genes upon which they act.
Advances in genome-wide measure-
ments of transcription factor binding and
chromatin state have begun to address
the former, because enhancers can now
be identified based on the presence of
particular chromatin modifiers and his-
tone modifications. With hundreds of
thousands of putative enhancers identi-
fied in the human genome, it is now imper-
ative that they be linked to their respective
genes in the context of both normal devel-
opment and pathogenesis. Enhancer
function can be affected by factors that
bind to the enhancer, chromatin modifi-
cations associated with enhancers, line-
age-specific signaling pathways, and mu-
tations altering the enhancer sequence
itself; the importance of these elements
in cancer is only beginning to be explored
(Herz et al., 2014).
EVI1 is a proto-oncogenic transcription
factor involved in the regulation of he-
matopoietic stem cells, and its overex-
pression has been linked to acutemyeloid
leukemia (AML) and myelodysplastic
syndrome (MDS) and carries a poor prog-
nosis (Glass et al., 2014). EVI1 deregula-
tion is often accompanied by a nearby
inversion inv(3) or translocation t(3;3) of
largely nongenic sequence, but mech-
anistic links between these rearrange-
ments and EVI1 expression changes
have remained poorly understood. Two
newstudies utilize orthogonal approaches
to dissect the regulatory potential of these
sequences and subsequently discoverCancer Celhow the genomic rearrangement of a sin-
gle enhancer element disrupts the regula-
tion of two genes involved in the onset of
AML (Figure 1).
In a recent study published in Cell, Gro¨-
schel et al. (2014) utilized functional geno-
mics and genome editing to characterize
chromosome 3q-rearrangements in pri-
mary AML samples and human cell
lines. Using an effective combination of
chromosome conformation capture with
ChIP-seq and RNA-seq, the authors iso-
lated a 9 kb element within commonly
translocated sequences, which physically
contacted the EVI1 promoter and stimu-
lated its expression. Analysis of p300
binding further allowed the elucidation of
a putative enhancer element, the excision
of which was shown to reduce EVI1
expression and limit proliferation, with
a marked skewing toward myelomono-
cytic differentiation. These changes were
largely phenocopied by EVI1 knockdown.
Further classification of the region sur-
rounding the enhancer indicated that it
may function as part of a so-called super
enhancer, with a characteristic H3K27ac
pattern and BRD4 binding (Whyte et al.,
2013). As such, cell lines containing the
3q-rearrangements were more respon-
sive to the BET bromodomain inhibitor
JQ1 and exhibited proliferation defects
and reduced EVI1 expression.
In a complementary study in this issue
of Cancer Cell, Yamazaki et al. (2014)
took advantage of a bacterial artificial
chromosome (BAC) system to recapitu-
late a human 3q-rearranged leukemia
in a mouse model. To this end, they uti-
lized a linked BAC strategy to precisely
generate the inv(3)(q21;q26) inversion
found in the human MOLM-1 leukemial 25, April 14, 2014 ª2014 Elsevier Inc. 407
Figure 1. A Single Enhancer Rearrangement Deregulates Two Oncogenic Drivers
(A) The distal enhancer normally drives GATA2 expression in a myeloid-specific manner. Inversion or
translocation of the locus simultaneously results in functional haploinsufficiency of GATA2 and upregula-
tion of EVI1.
(B) The enhancer can be deactivated through genome editing or pharmacologic BET inhibition. A novel
BAC-linking strategy allowed a faithful recapitulation of the rearrangement and disease in a mouse model.
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Previewscell line with and without the putative
enhancer element. They also generated
a control BAC containing the truncated
EVI1 gene alone. The resulting transgenic
mice underwent molecular and pheno-
typic profiling. The human EVI1 gene
was elevated in expression relative to
the endogenous mouse copy in hemato-
poietic stem and progenitor cells and
related compartments. The contribution
of the enhancer was best demonstrated
by the onset of hematologic pathologies.
Mice harboring BACs with the full inver-
sion developed splenomegaly and trans-
plantable leukemias, whereas those with
enhancer-deleted BACs resembled con-
trol mice. The leukemias showed both
myeloid and lymphoid properties, and,
although it is unknown how this arises, it
is in agreement with a recent finding that
EVI1 is expressed in a subset of pediatric
acute lymphoblastic leukemias (Konantz
et al., 2013).
Both studies establish that the regulato-
ry element in question is a distal enhancer
of GATA2 in the context of the wild-type
allele. In Gro¨schel et al. (2014), the
enhancer-EVI1 reporter assays estab-
lished a pattern of cell type-specific activ-
ity, indicating enhancer dependence on
the repertoire of available trans factors in408 Cancer Cell 25, April 14, 2014 ª2014 Elsthe myeloid lineage, which was their
first hint that the enhancer does not
belong to the ubiquitous housekeeping
gene RPN1 as previously hypothesized.
Indeed, further allele-specific analysis
confirmed that the enhancer normally
acts onGATA2 and that the 3q rearrange-
ment results in the functional haploinsuf-
ficiency of GATA2. Similarly, Yamazaki
et al. (2014) began their study by demon-
strating that a conserved homologous
sequence in mouse is acting as a hemato-
poietic-specificdistal enhancer ofGATA2.
Since GATA2 depletion has been linked
to AML, MDS, and Emberger/MonoMAC
syndromes (Bresnick et al., 2012), this
highlights the possibility of a single
enhancer rearrangement resulting in the
simultaneous upregulation of a proto-
oncogene and downregulation of a tumor
suppressor gene in a spatiotemporal spe-
cific manner.
Taken together, these two studies
emphasize the importance of noncoding
regulatory sequence rearrangements as
a driving mechanism for leukemogenesis.
While one paper takes advantage of
genomic tools to characterize human
samples and at least one potential thera-
peutic outlet, the other study establishes
a technique for the precise recapitulationevier Inc.of genomic rearrangements for full in vivo
characterization in mouse models. How-
ever, it should be noted that there may
be important ways in which the mouse
models differ from the human leukemias.
For example, when using human BACs
to express the translocated enhancer,
the mice do not have the haploinsuffi-
ciency of GATA2 as seen in the human
cells. Such a difference may lend insight
into the contribution of decreased
GATA2 expression in leukemogenesis
and requires further study. Regardless,
these findings illuminate a path to better
characterize the mechanistic and thera-
peutic implications of non-genic rear-
rangements and further highlight the fact
that a next frontier for cancer genomics
will focus on the importance of mutations
residing outside the coding exome.
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